CN106456764A8 - 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 - Google Patents

用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 Download PDF

Info

Publication number
CN106456764A8
CN106456764A8 CN201580028585.0A CN201580028585A CN106456764A8 CN 106456764 A8 CN106456764 A8 CN 106456764A8 CN 201580028585 A CN201580028585 A CN 201580028585A CN 106456764 A8 CN106456764 A8 CN 106456764A8
Authority
CN
China
Prior art keywords
pdl
antagonist
hpv negative
treating hpv
negative cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580028585.0A
Other languages
English (en)
Other versions
CN106456764A (zh
Inventor
K.斯特尔
M.C.雷贝拉托
J.A.巴拉克-哈斯金斯
P.B.罗宾斯
J.R.瓦塞利
R.A.斯图尔特
R.伊布拉希姆
A.沙拉比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CN106456764A publication Critical patent/CN106456764A/zh
Publication of CN106456764A8 publication Critical patent/CN106456764A8/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

在此提供的是治疗HPV阴性肿瘤的方法，该方法包括给予有效量的PDL-1/PD-1相互作用的拮抗剂(例如，抗PDL-1或抗PD-1抗体或其抗原结合片段)。
CN201580028585.0A 2014-05-29 2015-05-28 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 Pending CN106456764A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004731P 2014-05-29 2014-05-29
US62/004,731 2014-05-29
PCT/EP2015/061909 WO2015181331A1 (en) 2014-05-29 2015-05-28 Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers

Publications (2)

Publication Number Publication Date
CN106456764A CN106456764A (zh) 2017-02-22
CN106456764A8 true CN106456764A8 (zh) 2017-06-30

Family

ID=53276122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580028585.0A Pending CN106456764A (zh) 2014-05-29 2015-05-28 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂

Country Status (13)

Country Link
US (1) US20160031990A1 (zh)
EP (1) EP3149043A1 (zh)
JP (1) JP2017517525A (zh)
KR (1) KR20170007750A (zh)
CN (1) CN106456764A (zh)
AU (1) AU2015265859A1 (zh)
BR (1) BR112016027881A2 (zh)
CA (1) CA2949327A1 (zh)
IL (1) IL248836A0 (zh)
RU (1) RU2016151757A (zh)
SG (1) SG11201609468WA (zh)
TW (1) TW201625300A (zh)
WO (1) WO2015181331A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
MY194225A (en) 2015-03-13 2022-11-22 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
SG10201913303XA (en) 2015-07-13 2020-03-30 Cytomx Therapeutics Inc Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
EP3858859A1 (en) * 2015-07-14 2021-08-04 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
KR20230114331A (ko) 2016-09-14 2023-08-01 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
NZ759442A (en) 2017-06-01 2024-07-05 Cytomx Therapeutics Inc Activatable anti-pdl1 antibodies, and methods of use thereof
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11813279B2 (en) * 2018-12-21 2023-11-14 Aim Immunotech Inc. Compositions for cancer therapy and methods
WO2021150266A1 (en) * 2020-01-21 2021-07-29 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3279215T3 (da) * 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
AR091220A1 (es) * 2012-05-31 2015-01-21 Genentech Inc Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf
WO2015034519A1 (en) * 2013-09-03 2015-03-12 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
RU2701327C2 (ru) * 2013-09-11 2019-09-25 Медиммьюн Лимитед Антитела к b7-h1 для лечения опухолей

Also Published As

Publication number Publication date
KR20170007750A (ko) 2017-01-20
IL248836A0 (en) 2017-01-31
CA2949327A1 (en) 2015-12-03
JP2017517525A (ja) 2017-06-29
US20160031990A1 (en) 2016-02-04
CN106456764A (zh) 2017-02-22
BR112016027881A2 (pt) 2017-10-24
EP3149043A1 (en) 2017-04-05
WO2015181331A1 (en) 2015-12-03
AU2015265859A1 (en) 2016-12-15
SG11201609468WA (en) 2016-12-29
TW201625300A (zh) 2016-07-16
RU2016151757A (ru) 2018-07-02

Similar Documents

Publication Publication Date Title
CN106456764A8 (zh) 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
MX2022002364A (es) Anticuerpos anti-pd-l1.
WO2016014688A3 (en) Anti-pd-1 antibodies
WO2016062722A8 (en) Combination
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
WO2018093821A8 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EP3604337A4 (en) B7-H3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THE SAME, AND ITS MEDICAL USE
PH12016501456A1 (en) Antibody molecules to pd-1 and uses thereof
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2022014695A (es) Anticuerpos anti-gitr y sus usos.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
EP4324518A3 (en) Antibody molecules to tim-3 and uses thereof
PH12016501366A1 (en) Novel anti-baff antibodies
PH12019500552A1 (en) Antibody specifically binding to pd-1 and functional fragment thereof
EP3500294A4 (en) ANTI-PD-1 ANTIBODIES OR FRAGMENTS THEREOF FOR TREATING HEPATITIS B
EA201792058A1 (ru) Виротерапия комбинацией антител
EP4368207A3 (en) Ovarian cancer vaccines
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
EP3730519A4 (en) ANTIBODY OR ANTIGENT BINDING FRAGMENT THEREOF FOR THE SPECIFIC DETECTION OF B-CELL MALIGNOMAS, CHIMERA ANTIGEN RECEPTOR THEREOF AND USE THEREOF
WO2018102594A8 (en) Methods of treating solid tumors with anti-cd200 antibodies
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
EP3401336A4 (en) PCSK9 ANTIBODIES, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL USES THEREOF

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 62/004,731 2014.05.29 US

Number: 08

Volume: 33

CI01 Publication of corrected invention patent application
CI02 Correction of invention patent application

Correction item: Priority

Correct: 62/004,731 2014.05.29 US

Number: 08

Page: The title page

Volume: 33

CI02 Correction of invention patent application
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222

WD01 Invention patent application deemed withdrawn after publication